Business Context and Reporting Period
P3 Health Partners Inc. (P3) is a patient-centered, physician-led population health management company operating primarily in the Medicare Advantage (MA) market. The company utilizes a capitated, at-risk model where it receives fixed monthly payments to manage the total healthcare needs of attributed members. This Form 10-Q covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Operating Revenue | $345.3 million | $362.1 million | $1,074.3 million | $1,129.8 million |
| Net Loss | $(69.5) million | $(102.9) million | $(157.4) million | $(181.2) million |
| Net Loss Attributable to Controlling Interest | $(31.6) million | $(46.5) million | $(72.4) million | $(77.2) million |
| Adjusted EBITDA Loss | $(45.9) million | $(71.0) million | $(85.2) million | $(99.6) million |
| Medical Margin | $4.4 million | $0.5 million | $52.2 million | $78.2 million |
| Cash and Restricted Cash | $38.5 million | $68.1 million | $38.5 million | $68.1 million |
| Working Capital Deficit | $(288.3) million | $(212.3) million | $(288.3) million | $(212.3) million |
| Total Debt (Gross) | $312.2 million | $198.0 million | $312.2 million | $198.0 million |
Note: All share and per-share data has been retroactively adjusted for a 1-for-50 reverse stock split effected on April 11, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total operating revenue decreased by 5% year-over-year for both the quarter and the nine-month period. This was primarily driven by a 10% decrease in average at-risk members (from 128,400 to 115,900 in Q3) due to the strategic termination of underperforming payor contracts and affiliate providers.
- Improved Loss Profile: Despite lower revenue, the Net Loss improved significantly. Q3 2025 Net Loss was $69.5 million compared to $102.9 million in Q3 2024. This improvement was largely due to a Premium Deficiency Reserve (PDR) benefit of $23.7 million in Q3 2025, compared to a PDR expense of $18.2 million in the prior year period.
- Medical Expense Reduction: Medical expenses decreased by 8% in Q3 and 5% YTD, aligning with the reduction in member count.
- Increased Debt Load: Total gross debt increased from $198.0 million at year-end 2024 to $312.2 million at September 30, 2025. This increase resulted from new related-party financing transactions (VGS 4 and VGS 5 Promissory Notes) totaling approximately $60 million in the first nine months of 2025.
- Asset Sales: The company completed the sale of its Florida operations (P3 Florida) in May 2025 for approximately $0.1 million, resulting in an immaterial loss on disposal.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern within one year of the filing date. The company has a working capital deficit of $288.3 million and unrestricted cash of only $37.7 million. Continued operations depend on raising additional capital through debt or equity, which is not guaranteed.
- Debt Covenants and Interest: The company carries significant debt with high interest rates (ranging from 11% to 19.5%). Recent amendments to the Term Loan Facility extended the interest-only period but increased the interest rate to 15% after September 2025. The company is currently in compliance with covenants but faces risks regarding future compliance.
- Strategic Shifts: Management is actively exiting underperforming contracts to improve the profitability of remaining arrangements, evidenced by the PDR benefit. The focus is on maturing contractual arrangements to reduce future losses.
- Regulatory and Legal Risks:
- DOJ Investigation: The company received a Civil Investigative Demand (CID) from the DOJ in June 2024 regarding arrangements with insurance agents and brokers under the False Claims Act.
- California Solvency: The company must maintain a minimum "cash-to-claims ratio" of 0.75 to comply with California Department of Managed Health Care regulations. Failure could result in sanctions or termination of business in California.
- Nasdaq Listing: The company recently executed a 1-for-50 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. There is no assurance that the stock price will remain compliant in the future.
- Subsequent Event: In November 2025, the company formed a new Management Services Organization (MSO) with Commonwealth Primary Care ACO to manage ACO activities, with P3 holding an 80% interest.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure the additional capital required to fund operations for the next 12 months given the substantial doubt disclosure.
- Debt Service Capacity: Assess the impact of high-interest debt (up to 19.5% PIK) and the ability to meet mandatory prepayment triggers or covenant requirements.
- Member Retention: Monitor the trend in at-risk membership, which has declined due to contract terminations, and the success of new contract acquisitions.
- Medical Cost Ratios: Track the "Medical Margin" and "Medical Expense" as a percentage of revenue to ensure the strategic exit of underperforming contracts is yielding sustainable profitability.
- Regulatory Status: Confirm ongoing compliance with California DMHC solvency regulations and the status of the DOJ investigation.
- Stock Price Stability: Monitor the stock price post-reverse split to ensure continued compliance with Nasdaq listing requirements.